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In Alzheimer’s disease (AD) brain, exposure of axons
to Ab causes pathogenic changes that spread re-
trogradely by unknown mechanisms, affecting the
entire neuron. We found that locally applied Ab1-42
initiates axonal synthesis of a defined set of proteins
including the transcription factor ATF4. Inhibition of
local translation and retrograde transport or knock-
down of axonal Atf4 mRNA abolished Ab-induced
ATF4 transcriptional activity and cell loss. Ab1-42 in-
jection into the dentate gyrus (DG) of mice caused
loss of forebrain neurons whose axons project to
the DG. Protein synthesis and Atf4mRNAwere upre-
gulated in these axons, and coinjection of Atf4 siRNA
into the DG reduced the effects of Ab1-42 in the fore-
brain. ATF4 protein and transcripts were found with
greater frequency in axons in the brain of AD pa-
tients. These results reveal an active role for intra-
axonal translation in neurodegeneration and identify
ATF4 as a mediator for the spread of AD pathology.INTRODUCTION
b-amyloid (Ab) pathology is a central component of Alzheimer’s
disease (AD), and Ab1-42 is considered causative for most neuro-
degenerative alterations in AD (Hardy and Selkoe, 2002). Accu-
mulation of soluble oligomeric forms of Ab1-42 is positively corre-
lated with the onset of cognitive decline in AD brain, and elicits
neurodegeneration in primary neurons. Because axons and den-
drites are generally much larger than their cell bodies and project
over long distances in the brain, elevated Ab1-42 levels will first be
sensed by neurites. Consequently, pathogenic signaling mecha-
nisms will initially be triggered within neurites. Several aspects of
AD pathogenesis such as tau hyperphosphorylation or impaired
transport are first apparent in axons (Iqbal et al., 2009; Perlson
et al., 2010), and local application of Ab1-42 is sufficient to induceneurite degeneration (Ivins et al., 1998) and to interfere with retro-
grade axonal trafficking (Poon et al., 2013). Indeed, pathogenic
changes within axons may be primary events driving the devel-
opment of the classical pathological changes (Krstic and Knue-
sel, 2013). For example, in AD brains with amyloid plaques
restricted to the cortex, subcortical neurons with cortical projec-
tions degenerate, suggesting that axonal exposure to Ab1-42 is
sufficient to induce neurodegeneration over long distances (Liu
et al., 2008). Similarly, in AD patients’ brains, monoaminergic
neurodegeneration occurs in the locus coeruleus in the absence
of local Ab pathology (Marcyniuk et al., 1986). Therefore, in order
to understand the pathogenesis of AD, it is crucial to investigate
the intra-axonal signaling pathways triggered by Ab1-42 separate
from its effects on soma and dendrites.
Compartmentalized signaling is especially important for neu-
rons, the most morphologically polarized cells. In order to react
to stimuli in a spatially and temporally acute manner, axons are
able to synthesize a subset of proteins locally (Jung et al.,
2014). During development, intra-axonal protein synthesis is
crucial for growth cone behavior, axonal pathfinding, axonmain-
tenance, and retrograde signaling (Jung et al., 2014). After the
developmental period, the composition of the axonally localized
transcriptome changes (Gumy et al., 2011) and overall levels of
mRNAs and ribosomes are lower (Kleiman et al., 1994), and
mature axons have long been thought to be incapable of protein
synthesis. However, recent evidence shows that protein synthe-
sis persists in postdevelopmental central nervous system (CNS)
axons in vivo (Dubacq et al., 2009; Kar et al., 2014; Willis et al.,
2011; Yoon et al., 2012). Additionally, upon injury of mature
axons, a specific set of mRNAs and translation machinery are
rapidly recruited into axons, and proteins are locally synthesized
within mature axons (Rishal and Fainzilber, 2014). In contrast to
its well-established role during development and regeneration,
the role of intra-axonal protein synthesis in the context of neuro-
degenerative disorders remains unexamined.
Here we asked whether intra-axonal protein synthesis was
activated in response to Ab1-42 and functionally relevant for the
retrograde transmission of neurodegenerative signals across
brain regions. We report that axonal translation is activated inCell 158, 1159–1172, August 28, 2014 ª2014 Elsevier Inc. 1159
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Figure 1. Locally Applied Ab1-42 Oligomers
Induce Intra-Axonal Protein Synthesis
(A) Scheme of a microfluidic chamber used
to isolate axons of hippocampal neurons.
Neurons were cultured in the upper compart-
ment. Axons cross through two 200 mm-long
microgroove barriers into the axonal compart-
ments.
(B) Neuronal cell bodies were retrogradely labeled
by applying 1,10-dioctadecyl-3,3,3030-tetramethy-
lindocarbocyanine perchlorate (DiI) selectively to
the axons. Typically, between 40% (optical fields
proximal to the microgrooves) and 30% (distal
fields) of the neurons were labeled, indicating their
axons had crossed the microgrooves. The scale
bar represents 200 mm. DAPI, 40,6-diamidino-2-
phenylindole.
(C) Hippocampal neurons were cultured in mi-
crofluidic chambers for 9–10 DIV and axons were
treated with vehicle or Ab1-42 for 24 hr. Axons (left
micrographs) and cell bodies (right micrographs)
were immunostained for 4EBP1, p-4EBP1, S6, or
p-S6. Mean ± SEM of 23–25 optical fields per
condition (n = 5 biological replicates per group).
*p < 0.05; **p < 0.01; ***p < 0.001. The scale bars
represent 5 mm (left micrographs) and 20 mm (right
micrographs).
(D) Axons were treated with vehicle, Abscrambled,
Ab1-40, or Ab1-42 for 24 hr. Two hours prior to
fixation, axons were sequentially incubated
with AHA and 488-DIBO. Newly synthesized
proteins were detected by the fluorescence
signal (represented in pseudocolor). Mean ±
SEM of 25–35 optical fields per condition (n = 5–
7 biological replicates per group). ***p < 0.001;
n.s., not significant. The scale bar represents
5 mm.
(E) Axons were treated with vehicle or Ab1-42 for
48 hr or for 48 hr replacing the oligomer-containing
medium with fresh 50% conditioned medium after
24 hr. Two hours prior to sample processing,
axons were treated as in (D). Mean ± SEM of 35–
45 optical fields per condition (n = 7–9 biological
replicates per group). **p < 0.01. The scale bar
represents 5 mm.
(F) Axons were treated with vehicle or Ab1-42
for 24 hr. Two hours and 30 min prior to fixa-
tion, axons were sequentially incubated with
anisomycin or vehicle, and with AHA and alkyne-
488. Newly synthesized proteins were detected by their fluorescence signal (represented in pseudocolor). Mean ± SEM of 25–65 optical fields per condition
(n = 5–13 biological replicates per group). *p < 0.05; **p < 0.01; ***p < 0.001. The scale bar represents 5 mm.
See also Figure S1.response to Ab1-42. Axonal ATF4 synthesis is required for the
retrograde spread of Ab1-42-induced neurodegeneration, and
axons in the brain of AD patients showmore frequent localization
of ATF4 protein and mRNA.
RESULTS
Local Exposure to Ab1-42 Oligomers Induces Intra-
Axonal Protein Synthesis in Hippocampal Neurons
To investigate whether CNS neurons locally synthesize proteins
in axons in response to oligomeric Ab1-42, rat embryonic hippo-1160 Cell 158, 1159–1172, August 28, 2014 ª2014 Elsevier Inc.campal neurons were grown in tripartite microfluidic chambers,
which allow for the fluidic isolation of axons from cell bodies
and dendrites (Figures 1A and 1B) (Hengst et al., 2009; Taylor
et al., 2005). The small culture volume and the hydrophobicity
of microfluidic chambers influences the effective concentrations
of peptides (Toepke and Beebe, 2006). We used an Ab1-42 con-
centration (3 mM) that is equivalent to250 nM in regular cultures
(Figure S1A available online). Ab concentrations in normal aging
and AD brain range from 2 pM to 2 mM, respectively (Wang
et al., 1999). First, we determined the axonal abundance of two
molecular markers of translation: p-4EBP1 and p-S6. Levels
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Figure 2. Intra-Axonal Protein Synthesis
and Retrograde Transport Are Sequentially
Required for Ab1-42-Induced Somatic
Degeneration
(A) Axons were treated with vehicle or Ab1-42 for
24 or 48 hr. Fragmentation of axonal tubulin
(upper micrographs) or nuclear TUNEL staining
(lower micrographs) was measured. Mean ± SEM
of 25–55 axonal fields per condition (upper
graph; n = 5–11 biological replicates per group)
and 50–70 somatic fields per condition (lower
graph; n = 5–7 biological replicates per group).
**p < 0.01.
(B) Axons were treated with vehicle, Abscrambled, or
Ab1-40 for 48 hr. TUNEL-positive nuclei were
quantified. Mean ± SEM of 25–35 optical fields per
condition (n = 5–7 biological replicates).
(C) Immunostaining for Ab1-42 on axons and cell
bodies.
(D) Inhibitors were applied to axons during the last
6 hr of the 24 hr Ab1-42 treatment period. The
culture medium from the axonal compartments
was then replaced with 50% conditioned medium
and cells were allowed to recover. Cell death (left
panels) or survival (right panels) were assessed by
TUNEL and calcein staining, respectively. Mean ±
SEM of 50–70 somatic fields stained for TUNEL
per condition (left graph) and 25–31 somatic fields
stained for calcein (right graph) per condition (n =
5–7 biological replicates per group). *p < 0.05;
***p < 0.001.
(E) Inhibitors were applied to axons during the last
6 hr of the 48 hr experimental period. Cell death
and survival were assessed as before. Mean ±
SEM of 50–100 somatic fields stained for TUNEL
per condition (left graph) and 30 somatic fields
stained for calcein (right graph) (n = 5–10 biolog-
ical replicates). **p < 0.01; ***p < 0.001.
The scale bars represent 50 mm. See also
Figure S2.for 4EBP1 and p-4EBP1were nonsignificantly elevated, whereas
S6 and p-S6 levels were significantly increased in axons upon
Ab1-42 treatment (Figure 1C). Cell body levels of 4EBP1 and p-
4EBP1 did not change, and levels of S6 and p-S6 were slightly
reduced (Figure 1C). Ab1-42 selectively applied to the cell body
compartment caused an increase in both 4EBP1 and p-4EBP1
levels in the soma that did not propagate to the axonal com-
partment (Figures S1B and S1C). Next, we used bioorthogonal
noncanonical amino acid tagging to detect newly synthesized
proteins (Figure S1D). No local protein synthesis was detected
in axons treated for 24 hr with vehicle, a scrambled Ab1-42 pep-
tide, or soluble oligomeric Ab1-40, whereas Ab1-42-treated axons
exhibited a significant increase in L-azidohomoalanine (AHA)
incorporation (Figure 1D). Protein synthesis was detected in
axons exposed to Ab1-42 for 48 hr but not in axons treated for
24 hr with Ab1-42 followed by a 24 hr recovery period, indica-
ting that local protein synthesis does not persist after removal
of Ab1-42 (Figure 1E). AHA incorporation was prevented in the
presence of the protein synthesis inhibitors anisomycin andemetine in the axonal but not the cell body compartment (Fig-
ure 1F; Figure S1E). These results establish that axonally applied
Ab1-42 activates local protein synthesis within 24 hr.
Intra-Axonal Protein Synthesis and Retrograde
Transport Are Sequentially Required for
Neurodegeneration Triggered by Axonal Exposure
to Ab1-42
Application of Ab1-42 to axons did not increase axonal fragmen-
tation or cell death within 24 hr, and after 48 hr of Ab1-42 exposure
the number of TUNEL-positive neurons was significantly greater
whereas axonal fragmentation was not induced (Figure 2A). This
effect was specific for Ab1-42, as neither the scrambled peptide
nor Ab1-40 had any effect on cell death (Figure 2B). The observed
neurodegeneration at 48 hr is the result of pathogenic changes
originating in the axons, as only extremely little Ab1-42 was de-
tected in the soma (Figure 2C).
To test whether Ab1-42-induced intra-axonal protein synthesis
was required for the induction of cell death, axons were treatedCell 158, 1159–1172, August 28, 2014 ª2014 Elsevier Inc. 1161
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Figure 3. Atf4mRNA Is Recruited into Ab1-42-Treated Axons, and Axonal ATF4 Protein Is Locally Synthesized and Retrogradely Transported
(A) Log2 fold change for Atf4 mRNA as determined by real-time RT-PCR and DESeq2 (TMM, trimmed mean of M values). ***p < 0.001.
(B) Hippocampal neurons were cultured in microfluidic chambers for 9–10 DIV, axons were treated with vehicle, Abscrambled, or Ab1-40 for 18 hr, and axonal Atf4
mRNA levels were measured by quantitative FISH. Mean ± SEM of 25–30 optical fields per condition (n = 5–6 biological replicates).
(legend continued on next page)
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with vehicle or Ab1-42 for 24 hr in the absence or presence of ani-
somycin or emetine. To minimize toxic side effects of the protein
synthesis inhibitors, axons were exposed to them only during the
last 6 hr of the Ab1-42 treatment period. A significant increase in
TUNEL-positive and corresponding decrease in calcein-positive
neurons were observed upon treatment of axons with Ab1-42
(Figure 2D; Figure S2A). Inhibition of intra-axonal protein synthe-
sis completely abolished the effect of axonally applied Ab1-42,
demonstrating that intra-axonal protein synthesis is required
for Ab1-42-induced cell death.
To investigate whether transport from axons to soma was
required for Ab1-42-induced neurodegeneration, we used the
retrograde transport inhibitors ciliobrevin A and erythro-9-(2-hy-
droxy-3-nonyl)-adenine (EHNA). Both inhibitors significantly
reduced retrograde movement of axonal lysosomes in microflui-
dic chambers (Figure S2B). When applied during the last 6 hr of
the 24 hr Ab1-42 treatment period, ciliobrevin A only partially abol-
ished Ab1-42-mediated cell death whereas EHNA had no effect
(Figure 2D; Figure S2A). However, both inhibitors completely
abolished Ab1-42-dependent cell death when applied during the
last 6 hr of the 48 hr experiment, whereas application of anisomy-
cin at this time did not interfere with cell death (Figure 2E; Fig-
ure S2C), consistentwith our finding that axonal protein synthesis
is not persistent after the removal of Ab1-42 (Figure 1E). To ensure
that the effect of the inhibitors was not due to alterations in the
minute levels of Ab1-42 transported to the cell bodies, axons
were treated as before and cell bodies were immunostained for
Ab1-42. No correlation was found between somatic Ab1-42 levels
and cell death (Figure S2D). These results establish that sequen-
tial intra-axonal protein synthesis and retrograde transport are
required to transmit a neurodegenerative signal to the neuronal
cell bodies in response to axonal Ab1-42 application.
The Transcription Factor ATF4 Is Locally Synthesized in
Axons Exposed to Ab1-42
To identify proteins that might transmit the neurodegenerative
signal from axons to the soma, we performed RNA sequencing
(RNA-seq) on total RNA isolated from vehicle- and Ab1-42-treated(C) Axons were treated with Ab1-42 for the indicated times, and axonal Atf4mRNA
per condition (n = 5–8 biological replicates per group). The background fluorescen
0.05; **p < 0.01; ***p < 0.001.
(D) Neurons were cultured and treated as in (C). Axonal ATF4 protein levels were
fields per condition (n = 4–8 biological replicates per group). *p < 0.05; **p < 0.0
(E) Hippocampal neurons were cultured and treated as in (B). Three hours prior to
Axonal ATF4 protein levels were determined by quantitative immunofluorescence
per group). *p < 0.05; ***p < 0.001.
(F) Hippocampal neurons were cultured inmicrofluidic chambers for 8 DIV. Axons
four hours after transfection, axons were treated with vehicle or Ab1-42 for 18 hr. AT
SEM of 35–55 axonal fields per condition (n = 7–11 biological replicates per grou
(G) Axons were treated with vehicle or Ab1-42 for 24 hr, in the presence or absen
compartment for 3 hr. Axons were immunostained for ATF4 protein. Mean ± SEM
*p < 0.05.
(H) Axons were transfected with a control siRNA or siRNAs targeting Atf4mRNA an
ATF4 protein. Mean ± SEM of 30–40 axonal fields per condition (n = 6–8 biologic
(I) Neurons were cultured and treated as in (C). eIF2a and p-eIF2a levels were de
fields per condition (n = 4–7 biological replicates per group). *p < 0.05; **p < 0.0
(J) Neurons were cultured as in (B). Axons were treated for 18 hr with tunicamycin (
FISH. Mean ± SEM of 30 optical fields per condition (n = 6 biological replicates).
The scale bars represent 5 mm. See also Figure S3 and Table S1.axons and their cell bodies. Only mRNAs with higher expression
levels than previously reported nonaxonal transcripts were
included in our analysis (Figure S3A). The axonal transcriptomes
of control and treated axons showed only partial overlap (Fig-
ure S3B), indicating that exposure of axons to Ab1-42 triggers
the recruitment of a specific cohort of mRNAs (Table S1). Among
the axonally recruited mRNAs was the transcript coding for acti-
vating transcription factor 4 (ATF4). As a transcription factor,
ATF4 is a prime candidate for a retrogradely transported protein,
and it can suppress the transcription of memory-related genes
and activate the transcription of proapoptotic genes in response
to intracellular stress (Ameri andHarris, 2008). Additionally, ATF4
is a key molecule of the unfolded protein response (UPR)
pathway (Ron and Harding, 2012), which is activated in many
neurodegenerative diseases, possibly including AD (Ma et al.,
2013). Comparative analysis of the RNA-seq data sets and quan-
titative RT-PCR revealed an increase in axonal Atf4 abundance
following Ab1-42 treatment whereas levels in cell bodies were un-
changed, indicating that the upregulation of Atf4 in axons is likely
the result of increased axonal transport rather than transcription
(Figure 3A). No increase in Atf4 was detected in axons treated
with vehicle control, Abscrambled, or Ab1-40 for 18 hr (Figure 3B).
Axonal Atf4 mRNA levels determined by quantitative fluores-
cence in situ hybridization (FISH) were significantly increased
following 6 hr of Ab1-42 treatment and remained elevated until
at least 24 hr (Figure 3C). Similarly, ATF4 protein levels were
significantly increased at 6, 12, and 18 hr of Ab1-42 treatment
but dropped to lower than control levels at 24 hr (Figure 3D).
The increase in ATF4 at 18 hr was abolished by the local applica-
tion of protein synthesis inhibitors (Figure 3E) that did not affect
Atf4 mRNA localization in Ab1-42-treated axons (Figure S3C). To
unambiguously demonstrate local translation of Atf4 in axons,
we transfected Atf4-targeting siRNAs into axons. The RNAi
pathway is functional in axons, enabling knockdown of axonal
mRNAs without affecting somatodendritic mRNA levels (Hengst
et al., 2006). Neither Atf4 siRNA significantly altered Atf4 levels in
control axons but both blocked the increase of Atf4 in Ab1-42-
treated axons, with siRNA 1 decreasing Atf4 levels below controllevels were measured by quantitative FISH. Mean ± SEM of 25–40 axonal fields
ce was determined using a nontargeting probe (neg. probe) and set to zero. *p <
measured by quantitative immunofluorescence. Mean ± SEM of 20–40 axonal
1.
sample processing, axons were treated with DMSO, anisomycin, or emetine.
. Mean ± SEM of 25–35 axonal fields per condition (n = 5–7 biological replicates
were transfected with a control (ctrl.) siRNA or an siRNA targeting Atf4. Twenty-
F4 protein levels were measured by quantitative immunofluorescence. Mean ±
p). *p < 0.05; **p < 0.01.
ce of ciliobrevin A for 6 hr. Anisomycin was added to the cell body or axonal
of 30–40 axonal fields per condition (n = 6–8 biological replicates per group).
d treated with Ab1-42 and ciliobrevin A as in (G). Axons were immunostained for
al replicates per group). *p < 0.05.
termined by quantitative immunofluorescence. Mean ± SEM of 20–35 axonal
1.
Tm) or thapsigargin (Tg) andAtf4mRNA levels were determined by quantitative
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conditions (Figure S3D). In all subsequent experiments, siRNA 1
was used. The siRNA’s effect was restricted to axons, as ATF4
mRNA and protein levels were unchanged in cell bodies (Figures
S3E and S3F). Selective knockdown of axonal Atf4 completely
inhibited the increase in axonal ATF4 protein levels following
18 hr of exposure to Ab1-42 (Figure 3F).
To test whether the drop in axonal ATF4 abundance at 24 hr of
Ab1-42 treatment was due to ATF4 transport to the soma, we
applied retrograde transport inhibitors locally. Axonal ATF4
levels were significantly increased in axons after 24 hr of Ab1-42
treatment when retrograde transport was inhibited (Figures 3G
and 3F; Figure S3G), but axonal Atf4 mRNA levels were un-
changed (Figure S3H). Inhibition of intra-axonal but not somatic
protein synthesis completely abolished the Ab1-42-dependent in-
crease of axonal ATF4 in the presence of ciliobrevin A (Figure 3G).
ATF4 protein levels were significantly decreased in control or
Atf4 siRNA-transfected axons exposed to Ab1-42, and the accu-
mulation of ATF4 in ciliobrevin A-treated axons in response to
Ab1-42 was completely abolished in Atf4 siRNA-transfected
axons (Figure 3H). These results establish that local application
of Ab1-42 oligomers induces local ATF4 synthesis and its retro-
grade transport.
Ab1-42 Triggers Moderate eIF2a Activation
Atf4 belongs to a group of transcripts whose translation is acti-
vated by phosphorylation of the translation initiation factor
eIF2a (Ron and Harding, 2012). Total eIF2a levels in axons
were significantly increased by 12 hr of Ab1-42 treatment but re-
turned to control levels by 24 hr (Figure 3I). p-eIF2a levels were
significantly increased starting at 6 hr, first due to the increase
in total eIF2a and starting at 18 hr due to an increase in the
p-eIF2a/eIF2a ratio (Figure 3I). The increase in p-eIF2a was
much lower than the increase in Atf4 mRNA levels, indicating
that the increase in axonal ATF4 protein might be primarily driven
by increased Atf4 localization. At 24 hr, when we had observed
strong upregulation of general protein synthesis in axons, we
also detected a significant activation of eIF2a. There are four
mammalian eIF2a kinases, including the endoplasmic reticulum
(ER) stress-activated kinase PERK (Wek et al., 2006). Two acti-
vators of ER stress, tunicamycin and thapsigargin, did not trigger
axonal recruitment of Atf4 mRNA at 18 hr (Figure 3J) but both
efficiently initiated ER stress in neuronal cell bodies (Figure S4A),
suggesting that local ER stress does not phenocopy the effect of
Ab1-42 oligomers on Atf4 mRNA recruitment.
Axonally Synthesized ATF4 Induces Gene Expression in
Cell Bodies and Mediates Retrograde Somatic
Degeneration via CHOP
Next, we asked whether axonally derived ATF4 would function
as a transcription factor in response to local application of
Ab1-42 using an ATF4 firefly luciferase reporter gene construct.
We also included an ATF6 luciferase reporter (Wang et al.,
2000) to investigate whether Ab1-42 causes local ER stress lead-
ing to the activation of the ATF6 arm of the UPR. ATF4- or ATF6-
dependent luciferase transcription was efficiently detected upon
treatment of cell bodies with tunicamycin or thapsigargin for
24 hr (Figure S4A). No firefly luciferase activity of either construct
could be detected when axons were treated with vehicle or1164 Cell 158, 1159–1172, August 28, 2014 ª2014 Elsevier Inc.following 24 hr of Ab1-42 treatment (Figure 4A). However, 48 hr
after Ab1-42 exposure, a significant increase in cell body ATF4
abundance (Figure S4B) and transcriptional activity was ob-
served (Figure 4A, left graph) whereas ATF6 activity remained
undetectable (Figure 4A, right graph). Thus, axonal exposure to
Ab1-42 induces ATF4- but not ATF6-dependent transcription.
Next, we analyzed somatic expression of CHOP, a transcrip-
tional target of ATF4 (Averous et al., 2004), following 48 hr of
Ab1-42 treatment. CHOP expression was significantly increased
in cell bodies in response to axonal Ab1-42 but not Abscrambled
or Ab1-40 exposure (Figure 4B; Figure S4C).
We then asked whether activation of ATF4-dependent gene
expression was mediated by axonally synthesized ATF4. The
ATF4 increase in cell bodies after Ab1-42 exposure was fully
blocked by axonally applied anisomycin and partially blocked
by ciliobrevin A (Figure S4D). Thus, we treated axons with
Ab1-42 for 48 hr, adding ciliobrevin A 6 hr prior to sample process-
ing and assessed ATF4 activity via luciferase and CHOP expres-
sion assays. In both assays, inhibition of retrograde transport
completely abolished the effect of axonal Ab1-42 (Figures 4C
and 4D), and knockdown of axonal Atf4 prevented Ab1-42-
dependent transcription of luciferase, CHOP expression, or in-
crease of ATF4 in cell bodies (Figures 4E and 4F; Figure S4E),
demonstrating that axonally synthesized ATF4 is required for
ATF4-dependent gene expression after axonal Ab1-42 treatment.
Prolonged CHOP expression leads to cell death (Zinszner
et al., 1998), and therefore we asked whether Ab1-42-dependent
neurodegeneration wasmediated by axonally synthesized ATF4.
A significant induction of apoptosis and corresponding decrease
in calcein staining was found when control siRNA-transfected
axons were treated with Ab1-42, whereas depletion of axonal
Atf4mRNA fully rescued the cells (Figure 4G; Figure S4F). Addi-
tionally, Ab1-42 significantly increased the number of TUNEL-
positive nuclei in cell bodies transfected with control siRNA,
but Chop knockdown blocked Ab1-42-mediated neurodegenera-
tion (Figure 4H).
These results reveal that local application of Ab1-42 triggers the
intra-axonal synthesis and retrograde transport of ATF4, and that
these events are required for ATF4-dependent transcription
leading to CHOP-dependent cell loss.
Atf4 Is Locally Translated in Cholinergic Axons in the
Mouse Brain in Response to Ab
Next, we used a mouse model of semiacute amyloidopathy by
intrahippocampal injection of Ab1-42 oligomers to analyze the
in vivo relevance of our in vitro findings (Sotthibundhu et al.,
2008). In contrast to the more widely used transgenic mouse
models for Ab1-42 amyloidopathy, this model allows the spatially
restricted and temporally acute exposure of axons to elevated
Ab1-42 levels. Intrahippocampal injection of oligomeric Ab1-42 in-
duces neurodegeneration of basal forebrain cholinergic neurons
(BFCNs) within 2 weeks postinjection (Sotthibundhu et al., 2008).
BFCNs project their axons ipsilaterally to the hippocampus (Ler-
anth and Frotscher, 1989), allowing the contralateral injection of
vehicle to be utilized as a control in the same animal. Also, with
the exception of very few cholinergic neuronal cell bodies in
the dentate hilus, which can easily be avoided, choline acetyl-
transferase (ChAT) immunoreactivity in the dentate gyrus (DG)
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Figure 4. Axonally Synthesized ATF4 In-
duces ATF4-Dependent Gene Expression
in the Nucleus and Leads to Retrograde So-
matic Degeneration via CHOP
(A) Neurons were grown in microfluidic chambers
and cell bodies were transfected with the reporter
gene constructs 24 hr before local exposure
of axons to Ab1-42. Luciferase activities were
measured in cell lysates 24 and 48 hr after axons
had been treated with vehicle or Ab1-42. Data are
plotted as the ratio Firefly(RLU)/Renilla(RLU) and
normalized to vehicle. The maximum increase in
Firefly(RLU) activity per experiment was set to
100%. Mean ± SEM of 7–12 biological replicates
per condition. *p < 0.05. CMV, cytomegalovirus;
RLU, relative light units.
(B) CHOP levels were measured in cell bodies by
quantitative immunofluorescence after 48 hr of
local application of Ab1-42 to axons. Mean ± SEM
of 30–40 microscopy fields per condition (n = 6–8
biological replicates per group). *p < 0.05. The
scale bar represents 20 mm.
(C) Neurons were cultured as in (A) and axons were
exposed to Ab1-42 oligomers for 48 hr. Six hours
prior to luciferase measurement, axons were
exposed to vehicle or ciliobrevin A. Mean ± SEM of
6–10 biological replicates per condition. *p < 0.05.
(D) Axons were treated as in (C). CHOP levels were
measured in cell bodies by quantitative immuno-
fluorescence. Mean ± SEM of 35–45 optical fields
per condition (n = 7–9 biological replicates per
group). ***p < 0.001. The scale bar represents
20 mm.
(E) Neurons were cultured as in (A) and axons
were transfected with control or Atf4 siRNA 24 hr
before Ab1-42 treatment. Luciferase activities were
measured and are represented as in (A). Mean ±
SEM of 10–12 biological replicates per condition.
*p < 0.05.
(F) Axons were treated as in (E). CHOP levels in cell
bodies were measured by quantitative immuno-
fluorescence. Mean ± SEM of 30–40 microscopy
fields (n = 6–8 biological replicates per group).
***p < 0.001. The scale bar represents 20 mm.
(G) Neurons were cultured and treated as in (E). Cell bodies were processed for TUNEL staining. Mean ± SEM of 70–90 microscopy fields (n = 7–9 biological
replicates per group). ***p < 0.001. The scale bar represents 50 mm.
(H) Neurons were cultured as in (A) and cell bodies were transfected with control or Chop siRNA 24 hr before Ab1-42 treatment. Cell bodies were processed for
TUNEL staining after 48 hr of Ab1-42 application to axons. Mean ± SEM of 60 microscopy fields (n = 6 biological replicates per group). *p < 0.05. The scale bar
represents 50 mm.
See also Figure S4.is a specific marker for BFCN axons (Leranth and Frotscher,
1989).
We injected Ab1-42 into the DG and analyzed brain sections
2–7 days postinjection (DPI) at sites adjacent to the injection
where the DG layers were intact (Figure 5A; Figures S5A and
S5B). First, we confirmed the presence of oligomeric Ab1-42 in
these sites at 2, 4, and 7 DPI (Figure 5A). Atf4 mRNA was
readily detectable above background levels in cholinergic
axons in all layers of the DG 2, 4, and 7 DPI in Ab1-42- but
not vehicle-injected hemispheres (Figure 5B). ChAT staining
appeared to be more punctate in the vicinity of cell bodies,
especially in the granule cell layer (GCL), and colocalized with
synaptophysin staining in control hemispheres (Figure S5B),consistent with the known termination pattern of BFCN axons.
Puncta were more evident over time in Ab1-42-injected hemi-
spheres, suggesting synaptic/neuritic retraction. Atf4 granules
were frequently found in these puncta, possibly indicating their
localization to synaptic terminals and/or retracting synapses.
However, no reduction in ChAT-positive features was seen in
Ab1-42-injected hemispheres even 7 DPI (Figure S5C). Also,
no Atf4 above background was observed in granule cell bodies
under any condition (Figure S5D).
p-S6 and ATF4 levels were significantly increased within
ChAT-positive axons in the Ab1-42-injected side 7 DPI (Figures
5C and 5D). In granule cells, a moderate increase in p-S6 and a
strong upregulation of ATF4 were detected (Figures S5E andCell 158, 1159–1172, August 28, 2014 ª2014 Elsevier Inc. 1165
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Figure 5. Intrahippocampal Injection of Ab1-42 Induces Synthesis of ATF4 in BFCN Axons
(A) Presence of Ab1-42 in the DG of mice injected with vehicle and Ab1-42 oligomers 2–7 DPI. Four or five mice were analyzed per condition. ML, molecular layer;
GCL, granule cell layer; PCL, polymorphic cell layer. The scale bar represents 50 mm.
(B) FISH forAtf4mRNA in the DG ofmice injected with vehicle and Ab1-42. BFCN axons were identified by ChAT immunostaining. Cell bodies were counterstained
with DAPI. Mean ± SEM of measurements performed in three or four brain slices per mouse (n = 4 mice per group). Background fluorescence was determined
by the nontargeting probe signal and set to zero. *p < 0.05; **p < 0.01. The scale bars represent 20 mm and 5 mm (insets).
(C) Phosphorylation levels of ribosomal protein S6within ChAT-positive axons weremeasured by quantitative immunofluorescence on brain sections 7DPI. Mean
± SEM of measurements typically performed in four brain slices per mouse (n = 4 mice). ***p < 0.001. The scale bars represent 20 mm and 5 mm (insets).
(legend continued on next page)
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S5F), indicating that both axons and cell bodies respond to
Ab1-42 by increasing ATF4 levels. To confirm synthesis of
ATF4 within BFCN axons, both hemispheres of the brain
were injected with Ab1-42 and either a control siRNA or an
Atf4 siRNA. At 7 DPI, Atf4 siRNA caused a complete knock-
down of axonal Atf4 mRNA and significant reduction of ATF4
protein (Figures 5E and 5F) without causing axonal loss (Fig-
ure S5I). ATF4 protein was significantly reduced, and Atf4
mRNA remained undetectable in granule cells (Figures S5G
and S5H). These results demonstrate that axons in the mature
mammalian brain synthesize ATF4 and likely other proteins in
response to Ab1-42.
Axonally Synthesized ATF4 Is Required to Transmit a
Neurodegenerative Signal from the DG to BFCNs
Next, we investigated whether ATF4-dependent gene expres-
sion was induced in BFCNs. Fluorogold was coinjected into
both hemispheres of the brain to define the region of the basal
forebrain from which axons close to the injection site originated.
The unaffected detection of retrogradely transported fluorogold
in the basal forebrains of all mice (Figures S6A and S6B) sug-
gests that cholinergic afferents were functional and capable of
retrograde transport. ATF4 levels in BFCNs were significantly
increased at 2 and 4 DPI with a nonsignificant increase at 7
DPI (Figure 6A, upper panels and left graph). ATF4 induction
was evident in cholinergic neurons but not in all neurons present
in the basal forebrain (Figure S5C). CHOP-positive cholinergic
neurons were significantly increased at 7 DPI (Figure 6A, lower
panels and right graph), indicating that ATF4-dependent gene
expression was induced in the basal forebrain.
Next, we quantified the number of ChAT-positive neurons
to determine whether Ab1-42 injected in the hippocampus was
sufficient to induce neurodegeneration of BFCNs at some point
between 2 and 7 days. Ab1-42 injection did not change the num-
ber of ChAT-positive neurons in the forebrain at 2 or 4 DPI, but
caused a significant 20% reduction at 7 DPI (Figure 6B).
Conversely, no overall decrease was seen in NeuN-positive
neurons (Figure S6C, right graph), as expected considering
that not only BFCNs reside in the basal forebrain. We confirmed
these results using stereology as a complementary approach
(Figures S6D and S6E, left graphs). A significant 24% increase
in TUNEL-positive cells was found in the Ab1-42-injected hemi-
sphere compared to the control hemisphere (Figure 6C). These
results demonstrate that Ab1-42 injection into the hippocampus
induces retrograde degeneration of BFCNs.
We had observed that ATF4 and CHOP induction was uneven
across the basal forebrain, suggesting a greater response of
BFCNs in the nucleus of the diagonal band (NDB) than in the(D) ATF4 protein levels within ChAT-positive axons were measured by quantitativ
typically performed in four brain slices per mouse (n = 4 mice). *p < 0.05. The sc
(E) Mice were injected with Ab1-42 oligomers in both hemispheres of the brain. The
with an Atf4 siRNA. The presence of Atf4mRNA within ChAT-positive axons was
three brain slices per mouse (n = 3 mice). Background fluorescence was determi
represent 20 mm and 5 mm (insets).
(F) Mice were injected as in (E). ATF4 protein levels within ChAT-positive axons
Mean ± SEM of measurements typically performed in four brain slices per anima
See also Figure S5.medial septum (MS). Indeed, a significant decrease in BFCNs
was apparent only in the NDB, whereas cell death affected
both nuclei to a similar extent (Figure 6D; Figure S6D, right
graph), suggesting that cells other than BFCNs degenerate in
the MS in response to Ab1-42 injection. Next, we determined
whether ATF4-dependent signaling in the basal forebrain
required Ab1-42-dependent Atf4 synthesis in cholinergic axons
in the hippocampus. Consistent with our previous observations
that ATF4 protein was not significantly induced in the basal fore-
brain at 7 DPI, no reduction was detected in Atf4 siRNA-injected
hemispheres (Figure 6E, upper panels and left graph). However,
Ab1-42-dependent CHOP induction was significantly reduced by
Atf4 siRNA in the NDB (Figure 6E, lower panels and right graph).
Thus, synthesis of ATF4 in the hippocampus induces ATF4-
dependent signaling in BFCNs.
Finally, we sought to determinewhether axonally derived ATF4
was required for the loss of BFCNs. Coinjection of Atf4 siRNA
blocked the decrease in density of BFCNs in the NDB, in contrast
to the MS, which remained unaffected (Figure 6F; Figure S6F;
Table S2). When compared to non-siRNA conditions (dashed
lines in Figures 6F and 6G), Atf4 siRNA reduced the number of
TUNEL-positive cells in the NDB by63%but restored the num-
ber of ChAT-positive neurons to normal levels. This discrepancy
indicates that other cells in the forebrain die as well but only
BFCNs die in an ATF4-dependent manner. Additionally, axonally
synthesized ATF4might cause a loss of cholinergic phenotype in
BFCNs, as is suggested by the fact that the number of NeuN-
positive cells does not decrease significantly in the forebrain
upon Ab1-42 injection.
We observed a significant thinning of the GCL and increased
cell death in the DG exposed to Ab1-42 (Figure S6G), but Atf4
siRNA had no effect on the thickness of the GCL (Figure S6H,
left graph) and, far from rescuing dying cells, Atf4 siRNA exacer-
bated cell death in the DG (Figure S6H, right graph). Thus, the
decrease in BFCNs was not caused by neurodegeneration in
the hippocampus.
Atf4 mRNA Granules and ATF4 Protein Are Present in
Processes in Human AD Brains
Finally, we analyzed the presence of ATF4 mRNA and protein
in postmortem brain samples of eight AD patients and eight
age-matched controls. Axons and cell bodies containing Atf4
mRNA granules were found in the hippocampal formation in all
cases (Figure 7A). However, AD brains exhibited a higher fre-
quency of Atf4-containing axons in the hippocampus, subicu-
lum, and entorhinal cortex (Figure 7B). A decrease was observed
in Atf4-positive cell bodies in the hippocampus of AD brains, but
a higher frequency was found in the subiculum and entorhinale immunofluorescence on brain sections 7 DPI. Mean ± SEM of measurements
ale bars represent 20 mm and 5 mm (insets).
left hemisphere was coinjected with a control siRNA and the right hemisphere
analyzed by FISH 7 DPI. Mean ± SEM of measurements typically performed in
ned by the nontargeting probe signal and set to zero. *p < 0.05. The scale bars
were measured by quantitative immunofluorescence on brain sections 7 DPI.
l (n = 4 mice). **p < 0.01. The scale bars represent 20 mm and 5 mm (insets).
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Figure 6. Intra-Axonal Synthesis of ATF4 Leads to Neurodegeneration in the Adult Mouse Brain
(A) Mice were injected with vehicle in the left hemisphere of the brain and with Ab1-42 in the contralateral hemisphere. Sections of the basal forebrain were
immunostained for ChAT and ATF4 or CHOP 2–7 DPI. Mean ± SEM of positive cells relative to vehicle in approximately eight brain slices per animal (n = 4–5 mice
per condition). *p < 0.05. The scale bar represents 50 mm. Arrows indicate double-positive cells.
(B) ChAT-positive neurons in the basal forebrain of injected mice. Mean ± SEM of ChAT-positive neurons relative to the vehicle-injected side in approximately
eight brain slices per animal (n = 4–5 mice per condition). *p < 0.05. The scale bar represents 100 mm.
(C) TUNEL-positive cells in the basal forebrain of injected mice 7 DPI. Mean ± SEM of TUNEL-positive cells relative to the vehicle-injected side in approximately
eight brain slices per mouse (n = 5 mice). *p < 0.05. The scale bar represents 100 mm.
(D) Comparison of the effect of Ab1-42 injection on ChAT- and TUNEL-positive cells in the MS and NDB 7 DPI. Mean ± SEM of positive cells in approximately eight
brain slices per mouse (n = 5 mice). *p < 0.05; **p < 0.01.
(E) Ab1-42 injections were performed in both hemispheres of the brain. A control siRNA was coinjected into the left hemisphere and an Atf4 siRNA was coinjected
into the right hemisphere. Basal forebrain sections were immunostained for CHAT and ATF4 or CHOP. ATF4- and CHOP-positive cholinergic neurons were
quantified in the MS and NDB. Mean ± SEM of double-positive cells relative to control siRNA in approximately eight brain sections per animal (n = 5 mice). *p <
0.05. The scale bar represents 50 mm. Arrows indicate double-positive cells.
(legend continued on next page)
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Figure 7. Presence of Atf4 mRNA Granules
and ATF4 Protein in Axons and Axonal-like
Structures in the AD Brain
(A) Representative micrographs of Atf4 mRNA
granules in axons and cell bodies in human brain
samples. Panels 1–3: axons stained with Luxol fast
blue and a negative probe or an Atf4-targeting
probe. Atf4-containing axons are indicated with
arrows. Panels 4 and 5: examples of granule cells
stained with cresyl violet and a negative or Atf4-
targeting probe. The scale bars represent 20 mm
and 5 mm (insets).
(B) Cumulative frequency distributions of Atf4-
containing axons in the hippocampus, subiculum,
and entorhinal cortex of control and AD cases (n =
8 brains per condition).
(C) Cumulative frequency distributions of Atf4-
containing cell bodies in the hippocampus, sub-
iculum, and entorhinal cortex of control and AD
cases (n = 8 brains per condition).
(D) Representative micrographs of ATF4 protein in
processes and cell bodies in human brain sam-
ples. First panel: an ATF4-positive process (ar-
rows) in the vicinity of amyloid plaques (asterisks).
Second panel: a relatively intact ATF4-positive
process. Third panel: a beaded process. Fourth
panel: A positive cell body and neurite (arrows).
The scale bars represent 20 mm and 5 mm (insets).
(E) Cumulative frequency distributions of ATF4-
positive axons in the hippocampus, subiculum,
and entorhinal cortex of control and AD cases
(n = 8 brains per condition).
(F) Cumulative frequency distributions of ATF4-
positive cell bodies in the subiculum and entorhinal
cortex of control and AD cases (n = 8 brains per
condition).cortex (Figure 7C). In AD brains, ATF4-positive processes could
be observed in the vicinity of amyloid plaques (Figure 7D). ATF4
was found in relatively intact processes and in beaded neurites
(Figure 7D). More ATF4-positive axonal structures were found
in the subiculum and entorhinal cortex but not the hippocampus
of AD brains (Figure 7E). ATF4-positive cell bodies (Figure 7D)
were generally restricted to the subiculum and entorhinal cortex
for both control and AD cases, with a higher frequency in the en-
torhinal cortex for AD cases (Figure 7F). The increased fre-
quencies of ATF4 mRNA and protein in axons in the subiculum
and entorhinal cortex of AD patients are highly suggestive of
intra-axonal ATF4 synthesis in those regions of the brain that(F) Mice were injected as in (E). ChAT-positive neurons in the basal forebrain of injected mice were quantified
neurons relative to control siRNA in approximately eight brain slices per animal (n = 5 mice per condition). *
(G) TUNEL-positive cells in the forebrain of injected mice. Mean ± SEM of TUNEL-positive cells relative to co
mouse (n = 5 mice). **p < 0.01. The scale bar represents 100 mm.
See also Figure S6 and Table S2.
Cell 158, 1159–1172,are especially vulnerable in AD (Khan
et al., 2014). The results from human brain
samples, although correlative, closely
mirror our findings in hippocampal neu-
rons and in the adult mouse brain,providing evidence for the pathophysiological significance of
our proposed model (Figure S6I).
DISCUSSION
Several prior studies have demonstrated the importance of
local translation for axon maintenance (Yoon et al., 2012), mito-
chondrial function (Kar et al., 2014), and survival (Cox et al.,
2008), and suppression of local translation of lb2 mRNA causes
neurodegeneration in vivo (Yoon et al., 2012). Here we report
another dimension of local protein synthesis: in response to a
physiologically relevant neurodegenerative stimulus, axonalin the MS and NDB. Mean ± SEM of ChAT-positive
*p < 0.01. The scale bar represents 100 mm.
ntrol. siRNA in approximately eight brain slices per
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protein synthesis plays an active role in the transmission of
neurodegeneration. Rather than acting solely as a factor in
cellular homeostasis, local protein synthesis can be a major
component of neuronal dyshomeostasis under pathological
conditions.
Our finding that oligomeric Ab1-42 application to distal axons
triggers the rapid recruitment and local translation of a distinct
set of mRNAs is reminiscent of the activation of local translation
upon nerve injury (Rishal and Fainzilber, 2014). However, the
changes to the axonal transcriptome appear to be unique to
the exposure of distal axons to oligomeric Ab1-42. For example,
we find that the transcriptome of Ab1-42-treated axons contains
mRNAs of many AD-related genes, including transcripts for 4
out of the current list of 20 AD susceptibility loci (Lambert
et al., 2013): APP, ApoE, Clu, and FERMT2. These proteins
function in Ab1-42 production (APP) and metabolism (ApoE,
Clu), and have been implicated in tau pathology (FERMT2)
(Shulman et al., 2014). The posttranscriptional regulation of
these genes by Ab1-42 suggests that these proteins might func-
tion in feedback mechanisms downstream of amyloid pathology
in AD.
Transcriptional changes in AD brain or in response to Ab1-42
have been extensively studied in various experimental settings
(Miller and Geschwind, 2010). Although these studies have pro-
vided valuable insight into the signaling pathways affected in
Ab1-42 pathology, many of the mRNAs we identified as regulated
by Ab1-42 in axons have never before been described to be
changed in response to Ab1-42. This is likely due to the fact that
they are posttranscriptionally regulated, rather than by increased
promoter activity; in fact, we did not observe an overall up- or
downregulation for the vast majority of the axonally localized
mRNAs. Our study is thus a demonstration that posttran-
scriptional mechanisms of gene expression must be taken into
account when investigating changes in gene expression. Espe-
cially in morphologically polarized cells such as neurons,
mRNA localization can be as functionally relevant as transcrip-
tional regulation, and disorders of the nervous system cannot
be completely understood without the consideration of transla-
tional mechanisms.
We found that the increase of ATF4-positive BFCNs is greater
than the observed cell loss, suggesting a model in which ATF4 is
not directly leading to the transcription of proapoptotic genes but
rather triggers the expression of a variety of genes whose func-
tions cause pathogenic changes in the neurons, leading to cell
death as a secondary effect. The finding that Atf4 siRNA is
more efficient in rescuing the loss of ChAT-positive BFCNs
than in preventing apoptosis supports this model. Our finding
that BFCNs in theMS andNDB react differentially to Ab1-42 injec-
tion into the DG indicates that the exact transcriptional response
to axonally derived ATF4 differs between cell types. In fact, de-
pending on the context, ATF4 in neurons has variously been
described as proapoptotic, prosurvival, or memory suppressing
(Ameri and Harris, 2008). It is possible that in response to low
levels of eIF2a phosphorylation, as has been seen in AD patients’
brains and ADmodel mice (Ma et al., 2013), ATF4 actsmainly in a
neuroprotective and memory-suppressing manner whereas
upon prolonged exposure to Ab1-42 it can contribute to cell
death.1170 Cell 158, 1159–1172, August 28, 2014 ª2014 Elsevier Inc.Our study adds to a growing body of evidence that some tran-
scription factors are axonally synthesized (Ji and Jaffrey, 2014).
It remains an unanswered question what might be the advantage
of synthesizing a transcription factor in axons. In the case of
ATF4, an appealing idea is that local synthesismight favor dimer-
ization with an otherwise outcompeted binding partner. ATF4
binds promoter sequences either as a homodimer or a hetero-
dimer (Ameri and Harris, 2008). The relative abundance of poten-
tial binding partners in axons could favor the formation of other
heterodimers in axons rather than in cell bodies, leading to differ-
ential transcriptional activities.
AD progression is characterized by the spread of pathology
throughout the brain. Interferingwith the spreadwould be an ideal
approach to slow the decline of cognitive function that is charac-
teristic of AD. Our results unravel a mechanism for the spread of
disease that is based on the retrograde transport of ATF4. In this
model, the exposure of axons to pathological levels of Ab1-42
leads to neuron-wide pathogenic changes due to pathogenic al-
terations in gene expression. Our finding that siRNA-mediated
knockdown of Atf4 mRNA in axons alone is sufficient to prevent
neurodegeneration in response to acutely applied Ab1-42 in vivo
indicates an unexpected target for a future therapy. Indeed, small
molecules exist that could be used to repress ATF4 expression in
the brain (Moreno et al., 2013; Sidrauski et al., 2013).
In conclusion, we describe a pathway through which a neuro-
degenerative signal is transmitted from the periphery of neurons
to the soma acrossmacroscopic distances in the brain. Our find-
ings provide a mechanistic explanation for the spread of parts of
the pathological changes in AD brain and potentially indicate
new avenues for the development of therapeutic interventions
for AD.
EXPERIMENTAL PROCEDURES
Extended Experimental Procedures can be found in Supplemental
Information.
Axon-Specific Treatment In Vitro
To apply peptides, inhibitors, or siRNA specifically to axons, rat embryonic
hippocampal neurons were grown in tripartite microfluidic chambers with
two 200 mm-long microgroove barriers (Taylor et al., 2005). Synthetic Ab1-42
peptides were oligomerized (Stine et al., 2003) and applied to the axonal
compartment at 3 mM at 9–10 days in vitro (DIV). Whenever stated, the axonal
or cell body compartments were treated with 10 mM anisomycin, 500 nM
emetine, 30 mM ciliobrevin A, 10 mM EHNA, 10 mg/ml tunicamycin, or 1 mM
thapsigargin, or transfected with siRNA using NeuroPORTER (Genlantis).
RNA-Seq Analysis
Axons were exposed to Ab1-42 or vehicle for 24 hr. Total RNA was purified from
cell bodies and axons using the PrepEase RNA Isolation Kit (Affymetrix). cDNA
libraries were created using the TruSeq RNA Sample Preparation Kit (Illumina).
Sequencing was performed on an Illumina MiSeq instrument (paired end, 23
150 bp) with biological replicates. Reads were aligned to the rat genome (Rn5)
and counted using DESeq2 (Love et al., 2014).
Real-Time RT-PCR
Total RNA from cell bodies and axonal compartments was isolated as above,
reverse transcribed, and preamplified with the TaqMan PreAmp Kit (Life Tech-
nologies), and real-time RT-PCR was performed with TaqMan Gene Expres-
sion Master Mix and the Atf4 gene expression set (Rn00824644_g1). Gene
expression was normalized to input RNA.
Fluorescence In Situ Hybridization
Atf4mRNA in hippocampal neurons was detected by quantitative FISH using a
mixture of in vitro transcribed, digoxigenin-labeled riboprobes following estab-
lished protocols (Hengst et al., 2009). FISH on sections of mouse and human
brain was performed with the RNAscope Multiplex Fluorescent Reagent Kit
(Advanced Cell Diagnostics) according to the manufacturer’s instructions.
Luciferase Assay
Cell bodies of hippocampal neurons were transfected using NeuroPORTER
with an ATF4- (Promega) or ATF6-firefly reporter (Addgene) and a Renilla lucif-
erase construct (Promega). Firefly luciferase activity was measured 24 or 48 hr
after Ab1-42 treatment using the Dual-Luciferase Reporter Assay System
(Promega).
Ab1-42 Injection Experiments
Stereotaxic injections were performed following Sotthibundhu et al. (2008).
Nine- to 12-month-old C57Bl/6J mice were anesthetized and placed in a
stereotaxic frame (Stoelting). Stereotaxic injections were conducted using
convection-enhanced delivery at a rate of 0.5 ml/min using the Quintessential
Stereotaxic Injector (Stoelting) (coordinates from bregma: anterior-posterior,
2.00 mm; medial-lateral, ±1.3 mm; dorsal-ventral, 2.2 mm), resulting in an
estimated Ab1-42 concentration in the DG of 30 nM. Guidelines for the care
and use of laboratory animals were followed for all mouse experimentation.
Brain Samples
Postmortem brain samples of AD patients and age-matched controls were
obtained from the New York Brain Bank under a protocol approved by the
Institutional Review Board. Paraffin-embedded sections (8 mm) were analyzed
histochemically for the presence of ATF4 protein or by RNAscope for Atf4
mRNA.
Statistical Analyses
When comparing multiple groups, one-way ANOVA followed by Bonferroni
post hoc test was performed. To compare two groups, t tests were used.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, six
figures, and two tables and can be found with this article online at http://dx.
doi.org/10.1016/j.cell.2014.07.001.
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